Perspective Therapeutics, Inc. Common Stock

Financials

영업활동으로 인한 현금 -2.84 M-7.71 M-36.91 M-18.29 M-82.48 M -92.37 M 투자 활동으로 인한 현금 -410 K-284 K24.37 M-218.93 M41.23 M -62.76 M 재무활동으로 인한 현금 64.68 M56 K785 K289.38 M10.3 M 164.7 M 잉여 현금 흐름 -2.84 M-7.71 M-36.91 M-18.29 M-95.23 M -107.32 M

Isoray Inc. is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is a registered manufacturer with the FDA and holds multiple 510 clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu. The company went public in 2005. Isoray’s corporate headquarters is located at 350 Hills Street, Suite 106, Richland WA 99354.

CATX

Financials

Perspective Therapeutics, Inc. Common Stock

뉴스

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst Call - Slideshow (NYSE:CATX) 2026-05-04

Perspective Therapeutics - Decent Prospect In Radiopharmaceuticals Field (NYSE:CATX)

트루이스트, 퍼스펙티브 테라퓨틱스 주식에 ’매수’ 의견 재확인

Truist reiterates Buy on Perspective Therapeutics stock

RBC, Perspective Therapeutics 목표 주가 하향 조정

RBC cuts Perspective Therapeutics stock price target on model updates

Perspective Therapeutics, BTIG "매수" 등급 재확인

Perspective Therapeutics stock rating reiterated at Buy by BTIG

오펜하이머, Perspective Therapeutics에 ’아웃퍼폼’ 등급 유지

Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform

Perspective Therapeutics Q3 실적, 수익 에상치보다 저조